Figure 1.
Trial flowchart. NGS was performed on 202 primary MPN samples and 135 samples obtained 24 months after initiation of therapy with either HU or IFNα (IFNα-2a or IFNα-2b). One patient allocated to IFN-α died within 24 months.
Trial flowchart. NGS was performed on 202 primary MPN samples and 135 samples obtained 24 months after initiation of therapy with either HU or IFNα (IFNα-2a or IFNα-2b). One patient allocated to IFN-α died within 24 months.